<DOC>
	<DOCNO>NCT00540644</DOCNO>
	<brief_summary>The purpose study explore combination Revlimid® , oral cyclophosphamide prednisone ( RCP ) patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Phase II Study Revlimid® , Oral Cyclophosphamide Prednisone Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This phase II single institution trial patient newly diagnose multiple myeloma . Revlimid® 25 mg p.o . daily day 1-21 28-day cycle . Cyclophosphamide 50 mg p.o . BID daily day 1-21 28-day cycle . Prednisone 50 mg p.o . Q.O.D..</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients newly diagnose , symptomatic multiple myeloma base follow criterion : Presence Mcomponent serum and/or urine plus clonal plasma cell bone marrow and/or document clonal plasmacytoma PLUS one following : Calcium elevation ( 11.5 mg/dl ) [ 42.65 mmol/l ] Renal insufficiency ( 1.5 x ULN serum creatinine ) Anemia ( hemoglobin &lt; =10 g/dl 2 g/dl &lt; = normal ) Bone disease ( lytic lesion osteopenia ) Measurable disease define least one follow three measurement : Serum Mprotein &gt; =1 g/dl ( 10 g/l ) Urine Mprotein &gt; =200 mg/24 h Serum FLC assay : Involved FLC level &gt; =10 mg/dl ( &gt; =100 mg/l ) provide serum FLC ratio abnormal Measurable plasmacytoma NOTE : If patient meet criteria symptomatic multiple myeloma meet serum Mprotein , urine Mprotein serum FLC level state , percent plasma cell bone marrow use follow response . Laboratory test result within range : Absolute neutrophil count &gt; = 1.0 x 109/L Platelet count &gt; = 50 x 10 ( 9 ) /L Hemoglobin &gt; = 9 gm/dl Serum creatinine &lt; = 2.5mg/dL . Total bilirubin &lt; =1.5 x upper limit normal AST ( SGOT ) ALT ( SGPT ) &lt; = 3 x ULN Known hypersensitivity thalidomide The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Patients solitary plasmacytoma Patients uncontrolled diabetes Patients ≥ Grade 3 sensory neuropathy History cardiac disease , NYHA Class II great</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revlimid</keyword>
</DOC>